POLBF (Poolbeg Pharma) Net Margin % : 0.00% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Poolbeg Pharma Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Poolbeg Pharma's Net Income for the six months ended in Jun. 2024 was $-2.87 Mil. Poolbeg Pharma's Revenue for the six months ended in Jun. 2024 was $0.00 Mil. Therefore, Poolbeg Pharma's net margin for the quarter that ended in Jun. 2024 was 0.00%.

The historical rank and industry rank for Poolbeg Pharma's Net Margin % or its related term are showing as below:

POLBF's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -132.42
* Ranked among companies with meaningful Net Margin % only.

Poolbeg Pharma Net Margin % Historical Data

The historical data trend for Poolbeg Pharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poolbeg Pharma Net Margin % Chart

Poolbeg Pharma Annual Data

Trend

Dec21

Dec22

Dec23

Net Margin %

Poolbeg Pharma Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Net Margin %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Poolbeg Pharma's Net Margin %

For the Biotechnology subindustry, Poolbeg Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poolbeg Pharma's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Poolbeg Pharma's Net Margin % falls into.

Save Embed

;

Save Embed

;

Poolbeg Pharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Poolbeg Pharma's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-4.976	/	0
	=	%

Poolbeg Pharma's Net Margin for the quarter that ended in Jun. 2024 is calculated as

Net Margin	=	Net Income (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-2.873	/	0
	=	%

Poolbeg Pharma (OTCPK:POLBF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Poolbeg Pharma Net Margin % Related Terms

Thank you for viewing the detailed overview of Poolbeg Pharma's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Poolbeg Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poolbeg Pharma PLC (OTCPK:POLBF) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

POLB:UK 7JN:Germany

Address

42 New Road, Queen Mary BioEnterprises Innovation Centre, London, GBR, E1 2AX

Website

https://www.poolbegpharma.com

Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.